CYP3A activity: towards dose adaptation to the individual
Introduction: Co-medication, gene polymorphisms and co-morbidity are main causes for high variability in expression and function of the CYP3A isoenzymes. Pharmacokinetic variability is a major source of interindividual variability of drug effect and response of CYP3A substrates. While CYP3A genotypi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
26 March 2016
|
| In: |
Expert opinion on drug metabolism & toxicology
Year: 2016, Volume: 12, Issue: 5, Pages: 479-497 |
| ISSN: | 1744-7607 |
| DOI: | 10.1517/17425255.2016.1163337 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1517/17425255.2016.1163337
|
| Author Notes: | Nicolas Hohmann, Walter E. Haefeli, & Gerd Mikus |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1680008137 | ||
| 003 | DE-627 | ||
| 005 | 20230426084700.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191025s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1517/17425255.2016.1163337 |2 doi | |
| 035 | |a (DE-627)1680008137 | ||
| 035 | |a (DE-599)KXP1680008137 | ||
| 035 | |a (OCoLC)1341249323 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hohmann, Nicolas |d 1983- |e VerfasserIn |0 (DE-588)1018788999 |0 (DE-627)683426052 |0 (DE-576)356371816 |4 aut | |
| 245 | 1 | 0 | |a CYP3A activity |b towards dose adaptation to the individual |c Nicolas Hohmann, Walter E. Haefeli, & Gerd Mikus |
| 264 | 1 | |c 26 March 2016 | |
| 300 | |a 19 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 25.10.2019 | ||
| 520 | |a Introduction: Co-medication, gene polymorphisms and co-morbidity are main causes for high variability in expression and function of the CYP3A isoenzymes. Pharmacokinetic variability is a major source of interindividual variability of drug effect and response of CYP3A substrates. While CYP3A genotyping is of limited use, direct testing of enzyme function (‘phenotyping’) may be more promising to achieve individualized dosing of CYP3A substrates.Areas covered: We will discuss available phenotyping strategies for CYP3A isoenzymes and causes of intra- and interindividual variability of CYP3A. The impact of phenotyping on the dose selection and pharmacokinetics of CYP3A substrates (docetaxel, irinotecan, tyrosine kinase inhibitors, ciclosporin, tacrolimus) are reviewed. Pubmed searches were conducted during March-November 2015 to retrieve articles related to CYP3A enzyme, phenotyping, drug interactions with CYP3A probe substrates, and phenotyping-guided dosing algorithms.Expert opinion: While ample data is available on the choice appropriate phenotyping drugs (midazolam, alfentanil, aplrazolam, buspirone, triazolam), less clinical trial data is available concerning strategies to usefully guide dosing in the clinical practice. Implementation into the clinical routine necessitates further research to identify (1) an easy-to-use and cheap test for CYP3A activity that (2) adequately predicts drug exposure to (3) allow a sound decision on dose adaptation and hence (4) improve clinical outcome and/or reduce the intensity or frequency of adverse drug effects. | ||
| 650 | 4 | |a Dosing strategies | |
| 650 | 4 | |a microdosing | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a phenotyping | |
| 650 | 4 | |a TDM | |
| 700 | 1 | |a Haefeli, Walter E. |d 1958- |e VerfasserIn |0 (DE-588)124572359 |0 (DE-627)656806141 |0 (DE-576)340514221 |4 aut | |
| 700 | 1 | |a Mikus, Gerd |e VerfasserIn |0 (DE-588)110903137 |0 (DE-627)691097941 |0 (DE-576)336988710 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug metabolism & toxicology |d Abingdon, Oxon : Routledge, Taylor & Francis, 2005 |g 12(2016), 5, Seite 479-497 |h Online-Ressource |w (DE-627)588196576 |w (DE-600)2470760-0 |w (DE-576)302970746 |x 1744-7607 |7 nnas |a CYP3A activity towards dose adaptation to the individual |
| 773 | 1 | 8 | |g volume:12 |g year:2016 |g number:5 |g pages:479-497 |g extent:19 |a CYP3A activity towards dose adaptation to the individual |
| 856 | 4 | 0 | |u https://doi.org/10.1517/17425255.2016.1163337 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20191025 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 110903137 |a Mikus, Gerd |m 110903137:Mikus, Gerd |d 910000 |d 910100 |e 910000PM110903137 |e 910100PM110903137 |k 0/910000/ |k 1/910000/910100/ |p 3 |y j | ||
| 998 | |g 124572359 |a Haefeli, Walter E. |m 124572359:Haefeli, Walter E. |d 910000 |d 910100 |e 910000PH124572359 |e 910100PH124572359 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 1018788999 |a Hohmann, Nicolas |m 1018788999:Hohmann, Nicolas |d 910000 |d 910100 |e 910000PH1018788999 |e 910100PH1018788999 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1680008137 |e 3527289364 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Hohmann, Nicolas","given":"Nicolas","roleDisplay":"VerfasserIn","role":"aut","family":"Hohmann"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Walter E.","display":"Haefeli, Walter E.","family":"Haefeli"},{"family":"Mikus","roleDisplay":"VerfasserIn","role":"aut","given":"Gerd","display":"Mikus, Gerd"}],"language":["eng"],"name":{"displayForm":["Nicolas Hohmann, Walter E. Haefeli, & Gerd Mikus"]},"origin":[{"dateIssuedDisp":"26 March 2016","dateIssuedKey":"2016"}],"id":{"eki":["1680008137"],"doi":["10.1517/17425255.2016.1163337"]},"physDesc":[{"extent":"19 S."}],"relHost":[{"id":{"issn":["1744-7607"],"zdb":["2470760-0"],"eki":["588196576"]},"part":{"extent":"19","year":"2016","pages":"479-497","text":"12(2016), 5, Seite 479-497","issue":"5","volume":"12"},"recId":"588196576","note":["Gesehen am 03.09.15"],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.2005 -"],"title":[{"title_sort":"Expert opinion on drug metabolism & toxicology","title":"Expert opinion on drug metabolism & toxicology"}],"language":["eng"],"disp":"CYP3A activity towards dose adaptation to the individualExpert opinion on drug metabolism & toxicology","physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisher":"Routledge, Taylor & Francis ; Informa Healthcare","dateIssuedDisp":"2005-","publisherPlace":"Abingdon, Oxon ; London [u.a.]","dateIssuedKey":"2005"}]}],"title":[{"subtitle":"towards dose adaptation to the individual","title_sort":"CYP3A activity","title":"CYP3A activity"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 25.10.2019"],"recId":"1680008137"} | ||
| SRT | |a HOHMANNNICCYP3AACTIV2620 | ||